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Abstract
Background: The RING domain-containing protein RING finger protein 11 (RNF11) is a member of the A20
ubiquitin-editing protein complex and modulates peripheral NF-κB signaling. RNF11 is robustly expressed in
neurons and colocalizes with a population of α-synuclein-positive Lewy bodies and neurites in Parkinson disease
patients. The NF-κB pathway has an important role in the vertebrate nervous system, where the absence of NF-κB
activity during development can result in learning and memory deficits, whereas chronic NF-κB activation is
associated with persistent neuroinflammation. We examined the functional role of RNF11 with respect to canonical
NF-κB signaling in neurons to gain understanding of the tight association of inflammatory pathways, including
NF-κB, with the pathogenesis of neurodegenerative diseases.
Methods and results: Luciferase assays were employed to assess NF-κB activity under targeted short hairpin RNA
(shRNA) knockdown of RNF11 in human neuroblastoma cells and murine primary neurons, which suggested that
RNF11 acts as a negative regulator of canonical neuronal NF-κB signaling. These results were further supported by
analyses of p65 translocation to the nucleus following depletion of RNF11. Coimmunoprecipitation experiments
indicated that RNF11 associates with members of the A20 ubiquitin-editing protein complex in neurons.
Site-directed mutagenesis of the myristoylation domain, which is necessary for endosomal targeting of RNF11,
altered the impact of RNF11 on NF-κB signaling and abrogated RNF11’s association with the A20 ubiquitin-editing
protein complex. A partial effect on canonical NF-κB signaling and an association with the A20 ubiquitin-editing
protein complex was observed with mutagenesis of the PPxY motif, a proline-rich region involved in Nedd4-like
protein interactions. Last, shRNA-mediated reduction of RNF11 in neurons and neuronal cell lines elevated levels of
monocyte chemoattractant protein 1 and TNF-α mRNA and proteins, suggesting that NF-κB signaling and
associated inflammatory responses are aberrantly regulated in the absence of RNF11.
Conclusions: Our findings support the hypothesis that, in the nervous system, RNF11 negatively regulates canonical
NF-κB signaling. Reduced or functionally compromised RNF11 could influence NF-κB-associated neuronal functions,
including exaggerated inflammatory responses that may have implications for neurodegenerative disease
pathogenesis and progression.
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Background
The NF-κB transcription factor has important roles in the
regulation of programmed cell death, cell proliferation and
differentiation, innate and adaptive immune responses,
and inflammation [1]. Defects in NF-κB signaling, such as
persistent activation, can contribute to the pathology of
several cancers and inflammatory diseases [1]. NF-κB also
has notable ramifications in the vertebrate nervous system,
where the absence of NF-κB activity during develop-
ment can result in abnormal neurite branching and loss
of learning and memory. Notably, persistent activation
of NF-κB signaling is associated with chronic neuroin-
flammation and is implicated in the progression of neu-
rodegenerative diseases [2-11].
To ensure regulated transient activity, NF-κB signaling
is tightly controlled with several layers of modulation.
Several NF-κB target genes can function as NF-κB inhi-
bitors, such as A20 (also known as TNF-α-induced pro-
tein 3, or TNFAIP3), inhibitors of NF-κB (IκBs) and
cylindromatosis [12,13]. The ubiquitin-editing protein
A20 is a key negative regulator of NF-κB signaling and
functions downstream of innate immune receptors such
as TNF receptor (TNFR) and Toll-like receptors (TLRs)
[14]. A20-deficient mice have widespread inflammation
in all organ systems [15], and recent studies have indi-
cated that the regulatory function of A20 is dependent
upon interactions with the E3 ligase Itch (also known as
AIP4), Tax1 (human T-cell leukemia virus type I) binding
protein 1 (TAX1BP1) and RNF11 (RING finger protein
11) [16-19].
RNF11 is a 154-amino acid protein with differential ex-
pression in cancer, including breast, pancreatic and colon,
as well as in Parkinson disease (PD) [20-23]. RNF11 con-
tains a RING H2 finger domain in its C-terminus, which is
a hallmark characteristic of an E3 ubiquitin ligase [24].
RNF11 enhances TGF-β signaling through interactions
with Smad4 and Smurf2 [23,25-27]. It is also an essential
component of the A20 ubiquitin-editing complex in the
periphery and can negatively regulate NF-κB signaling in
human monocytic cell lines [19].
We have previously demonstrated that RNF11 is differen-
tially expressed throughout the brain and that neurons
express higher levels of RNF11 compared to glial cells in
tissue [20] (see Figure 1D); however, the function of RNF11
in the nervous system remains to be determined. On the
basis of the characterization of RNF11 in monocytic cell
lines [19], we hypothesized that neuronal RNF11 modulates
NF-κB activity by interacting with the A20 ubiquitin-edit-
ing complex. To establish the effects of neuronal RNF11 on
NF-κB signaling, targeted knockdown of endogenous
RNF11 was employed in human neuroblastoma cells and
primary cortical neurons. Reduced RNF11 expression
resulted in persistent NF-κB signaling, and association of
RNF11 with the A20 ubiquitin-editing protein complex
was demonstrated in neuroblastoma cells and primary
cortical neuron cultures. Site-directed mutagenesis of
RNF11 functional motifs revealed that the myristoyla-
tion domain was necessary for RNF11’s association
with the A20 ubiquitin-editing protein complex as well
as RNF11’s regulation of canonical NF-κB signaling.
Furthermore, depletion of RNF11 resulted in aberrant
regulation of inflammatory signaling in neuroblastoma
cells and primary cortical neurons. Taken together,
these studies support a role for RNF11 in regulated ac-




SH-SY5Y and neuroblastoma N2A cells were purchased
from the American Type Culture Collection (Manassas,
VA, USA). SH-SY5Y cells were cultured in Eagle’s minimal
essential medium supplemented with Earle’s balanced salt
solution, L-glutamine, 10% fetal bovine serum (FBS)
(HyClone Laboratories, Logan, UT, USA), 1% nonessential
amino acids (BioWhittaker, Inc, Walkersville, MD, USA)
and 1% penicillin/streptomycin (BioWhittaker). N2A cells
were cultured in DMEM/Ham’s F-12 nutrient mixture
(supplemented with 10% FCS (HyClone Laboratories), 1%
nonessential amino acids and 1% penicillin/streptomycin.
Primary cortical neurons were prepared from wild-type
C57BL/6 mice at embryonic day 18 as previously
described [28]. Cells were dissociated by trituration
through a Pasteur pipette and plated on 0.25 mg/ml poly-
L-lysine-coated dishes in neurobasal medium (Invitrogen,
Carlsbad, CA, USA) containing B-27 supplement (Invi-
trogen), 2 mM L-glutamine and 1% penicillin/strepto-
mycin. Cytosine arabinoside was added at a final
concentration of 5 μM on day 3 in vitro to control pro-
liferation of nonneuronal cells. After 8 days in vitro,
neuron-enriched cultures were used for experiments.
Other research groups have confirmed that more than
95% of the cells in these culture preparations are posi-
tive for neuronal markers [29,30]. Primary microglia and
astrocytes were obtained from 1-day-old wild-type
C57BL/6 mice as described elsewhere [31,32]. Briefly,
cells were dissociated into a suspension by trituration
with a Pasteur pipette and plated onto six-well plates
coated with 0.05 mg/ml poly-D-lysine and grown in
DMEM (Invitrogen) supplemented with 25 mM glucose,
10% heat-inactivated horse serum, 10% heat-inactivated
FBS, 2 μM glutamine and 1% penicillin/streptomycin. At
the end of day 12 in vitro, floating microglia were sepa-
rated from the stationary cultures and centrifuged at
80 g for 5 minutes to obtain a pellet of nearly pure
microglia, which were then plated directly into poly-D-
lysine-coated dishes. All cultures were maintained at
37°C in 5% CO2.
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Antibodies
The following antibodies were used: A20 (ab13597;
Abcam, Cambridge, MA, USA), β-actin (ab6276;
Abcam), Flag (F1804; Sigma-Aldrich, St Louis, MO,
USA), histone 1 (MAB052; Millipore, Billerica, MA,
USA), Itch (611198; BD Transduction Laboratories, San
Diego, CA, USA), p65 (for immunocytochemistry,
C22B4; Cell Signaling Technology, Beverly, MA, USA),
p65 (for Western blotting, 3034; Cell Signaling Technology),
RNF11 (described previously [20]) and V5 (MCA1360; AbD
Serotec, Oxford, UK).
Plasmids and transfections
Human RNF11 cDNA was originally subcloned into
pcDNA3.1(+) (Invitrogen) using Kpn1 and Not1 restric-
tion sites as described previously [20]. Wild-type RNF11
was cut out of pcDNA and into pFUGW with BamHI
and Asc1. A V5 sequence was added to the N-terminus
of the RNF11 sequence and was PCR-amplified into the
plasmid. The NF-κB luciferase vector (pGL4.32[luc2P/
NF-κB/Hygro]) and internal control Renilla vector
(pGL4.74[hRluc/TK]) were purchased from Promega
(Madison, WI, USA). The NF-κB luciferase vector
Figure 1 Knockdown of RNF11 exaggerates inflammatory responses following TNF-α treatment. (A) and (B) Stably transduced SH-SY5Y
short hairpin RNA (shRNA)-RNF11 and shRNA-Scramble cells were exposed to 0 or 10 ng/ml TNF-α for 24 hours. The relative amount of mRNA
expression in stimulated and unstimulated cells was calculated using quantitative RT-PCR (qRT-PCR) and glucuronidase β (GUSB) as an internal
control. (C) Stably transduced SH-SY5Y shRNA-RNF11 and shRNA-Scramble cells were exposed to 0 or 10 ng/ml TNF-α for 4 hours before cells
were rinsed and fresh media were replaced in the plate. Media were collected after 20 hours and analyzed for TNF-α protein levels using a
human TNF-α ELISA. ND, not detectable. (D) Murine primary cultures were harvested, and qRT-PCR was used to measure relative RNF11 mRNA
levels. (E) Murine primary cortical neurons were treated with cytosine arabinoside and transduced with shRNA-Scramble or shRNA-RNF11
lentivirus. Cells were exposed to 0 or 10 ng/ml TNF-α for 4 or 24 hours, and mRNA levels were examined by qRT-PCR. (F) Murine primary cortical
neurons were transduced with shRNA-Scramble or shRNA-RNF11 lentivirus. Cells were exposed to 0 or 10 ng/ml TNF-α for 4 or 24 hours, and
protein levels of monocyte chemoattractant protein 1 (MCP-1) were measured using a mouse MCP-1 ELISA. qRT-PCR values are expressed as
mean comparative cycle threshold ± SEM with GUSB (for SH-SY5Y cells) or glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (for primary
cultures) levels as an internal control for three independent experiments. ELISA values are expressed as averages of protein levels extrapolated
from standard curve analysis from three independent experiments. ***P< 0.001.
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contains a (GGGAATTTCC)5 NF-κB response element
protein promoter. Flag-A20 was a kind gift from Dr Ed-
ward W Harhaj (Microbiology and Immunology, Miller
School of Medicine, University of Miami, Miami, FL,
USA). Transient transfections of SH-SY5Y and N2A
cells were performed using Lipofectamine 2000 trans-
fection reagent (Invitrogen) according to the manufac-
turer’s protocol.
RNA interference
Individual siRNA duplexes were purchased from Dharma-
con Inc (Chicago, IL, USA) and tested for knockdown of
RNF11 using quantitative RT-PCR (qRT-PCR) in SH-SY5Y
cells (not shown). The most effective sequence was cloned
into pFH1UGW backbone by introducing Nhe1 and Pac1
overhangs at each end of the duplex. The sense sequence
for RNF11 shRNA was 5′-GAT GAC TGG TTG ATG
AGA T-3′, and the antisense sequence was 5′-ATC TCA
TCA ACC AGT CAT C-3′. All constructs were verified by
restriction enzyme digestion and sequencing. Lentiviruses
for shRNA-RNF11 and shRNA-Scramble constructs were
produced by the Emory University Viral Vector Core facility
(Atlanta, GA, USA).
Site-directed mutagenesis
Site-directed mutagenesis of RNF11 (G2A, Y40A, H119/
122A or H2, I101A, C99A and silent mutations at Q72/R73
to confer shRNA resistance) was performed using the Quik-
Change II XL Site-Directed Mutagenesis Kit (Stratagene,
Santa Clara, CA, USA) according to the manufacturer’s
instructions using N-terminal V5-tagged RNF11 as a tem-
plate. The primers for the myristoylation mutant (G2A)
were as follows: forward, 5′-CTC GAT TCT ACG ACC
GGTATG GCG AAATGC CTC AAATCC CCC ACC-3′,
and reverse, 5′-GGT GGG GGA TTT GAG GCA GTT
CGC CAT ACC GGT CGT AGA ATC GAG-3′. The pri-
mers for the PPPY domain mutant (Y40A) were as follows:
forward, 5′-GCC GCC GCC GCC AGC TCA GGA ACA
AGT TCC AG-3′, and reverse, 5′-CTG GAA CTT GTT
CCT GAG CTG GCG GCG GCG GC-3′. The primers for
the RING domain mutant (H2) were as follows: forward,
5′-CGA TTT CTG CCG TGC ATG GCC ATC TAT GC-
3′, and reverse, 5′-CTA TAC AGT CCA GGG CAT AGA
TGG CCA TG-3′. The primers for the RING domain mu-
tant (I101A) were as follows: forward 5′-GAT CCG GGA
GTG TGT GGC CTG TAT GAT GGA CTT TG-3′, and
reverse, 5′-CAA AGT CCA TCA TAC AGG CCA CAC
ACT CCC GGA TC-3′. The primers for the RING domain
mutant (C99A) were as follows: forward, 5′-GAT CCG
GGA GGC TGT GAT CTG TAT GAT GGA C-3′, and re-
verse, 5′-GTC CAT CATACA GAT CAC AGC CTC CCG
GAT C-3′. The primers for shRNA-RNF11 resistance were
as follows: forward, 5′-CAG CTG ACT GAA GAG GAA
CAA ATT AGG ATA GCT CAG AGG ATA GGT C-3′,
and reverse, 5′-GAC CTATCC TCT GAG CTATCC TAA
TTT GTT CCT CTT CAG TCA GCT G-3′. The primers
were utilized for PCR amplification, which was performed
according to the company’s protocol. All constructs were
verified by restriction enzyme digestion and sequencing.
TNF-α stimulation and luciferase assays
Recombinant TNF-α was purchased from R&D Systems
(Minneapolis, MN, USA). All stimulations of cells with
TNF-α were preceded by a 1-hour serum starvation
period. Cells were stimulated with 10 ng/ml TNF-α at
the indicated times. SH-SY5Y cells were transfected with
the luciferase and Renilla plasmids for 24 hours. Cells
were stimulated with TNF-α for 6 hours. Cell lysates
were prepared in Passive Lysis 1× Buffer (Promega).
Luciferase activity was measured using the Dual-Lucifer-
ase Reporter Assay System (Promega) according to the
manufacturer’s protocol. Firefly luciferase values were
normalized according to Renilla luciferase values. Luci-
ferase results are presented as fold changes relative to
the untreated control sample. Control samples with luci-
ferase, Renilla luciferase or vector transfection were
assayed to confirm the specificity of luminescence.
Immunocytochemistry
SH-SY5Y cells were grown on coverslips coated with
Matrigel (BD Biosciences, San Diego, CA, USA), and pri-
mary cortical neurons were grown on coverslips coated with
poly-L-lysine (Sigma-Aldrich. After being manipulated, cells
were fixed with 2% paraformaldehyde and immunostained
as described previously [20] with an antibody against p65.
Cell nuclei were stained with Hoechst 333258 (Molecular
Probes/Invitrogen). The fluorophore-conjugated secondary
antibody used was goat anti-mouse Rhodamine Red-X
(Jackson ImmunoResearch Laboratories, West Grove, PA,
USA). For p65 analysis, coverslips were imaged at ×40 mag-
nification using an Olympus BX51 Fluorescence Micro-
scope (Olympus America, Inc, Melville, NY, USA), and
colocalization of p65 and 4′,6-diamidino-2-phenylindole in
GFP-positive cells was quantified as described previously
[33]. For each condition, at least 100 cells were quantified
in the SH-SY5Y cell experiments and at least 50 cells were
quantified in the primary neuron experiments. The per-
centage of p65 positive pixels above threshold intensity
which overlapped with Hoechst staining was calculated for
each cell. An area near the perimeter of the cell was used
as background. For each experiment, the fold change in
percentage of p65-positive pixels was normalized to un-
stimulated cells.
Quantitative real-time PCR
Total RNA was isolated from cells using a standard TRI-
zol reagent (Invitrogen) extraction protocol. RNA was
converted to cDNA using a High Capacity cDNA
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Reverse Transcription Kit (Ambion, Austin, TX, USA).
Real-time PCR was performed with a 7500 Fast RT-PCR
System (Applied Biosystems, Foster City, CA, USA)
using 20 ng/μl cDNA, TaqMan Universal PCR Master Mix
(Applied Biosystems) and gene-specific TaqMan probes
(Applied Biosystems) against RNF11 (Hs00702517_s1,
Mn00450014_m1), TNF-α (Hs00174128_m1), A20
(Hs00234712_m1), monocyte chemoattractant pro-
tein 1 (MCP-1) (Mm00441242_m1), glucuronidase-β
(GUSB) (Hs99999908_m1) or glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) (4308313). For each
RNA sample, each primer set was run in triplicate.
Gene expression was normalized to the internal
control GUSB or GAPDH and relative expression
was calculated for each gene using the comparative
cycle threshold method.
Immunoblotting
Immunoblotting was performed as previously described
[20]. Cells were transfected for 24 hours with the indicated
plasmids and rinsed with PBS, then harvested in 100 μl
mM TrisHCl, pH 7.6, 150 mM NaCl, 0.1% Triton X-100,
1% Nonidet P (NP)-40, Halt Phosphatase Inhibitor Cock-
tail (Pierce Biotechnology, Rockford, IL, USA) and prote-
ase inhibitor cocktail (PIC) (Roche Diagnostics,
Mannheim, Germany). Samples were spun at 14,000 rpm,
and protein concentration was determined using the DC
Protein Assay (Bio-Rad Laboratories, Hercules, CA, USA).
Samples were separated by SDS-PAGE and transferred
onto polyvinylidene fluoride membranes. Immunoblotting
was performed using primary antibodies against A20, β-
actin, Flag, histone 1, Itch, p65, RNF11 or V5. Membranes
were scanned using the Odyssey Imaging System (LI-COR
Biosciences, Lincoln, NE, USA). β-actin was used as a load-
ing control where appropriate.
Co-immunoprecipitation
Immunoprecipitation (IP) experiments were performed
as described previously [34]. Equal amounts of protein
were used for pull-down assays. Cell lysates were cleared
with mouse immunoglobulin plus protein A Sepharose
beads (Invitrogen) for 30 minutes at 4°C. IP experiments
were then performed using antibodies against Flag, Itch,
RNF11 or V5. Control IP experiments were performed
with beads alone or with empty vector to demonstrate
specificity. Immunoprecipitates were assessed by immu-
noblot analysis. Densitometric measurements for A20,
Itch or RNF11 immunoreactivity in RNF11 immunopre-
cipitates were performed using ImageJ software (National
Institutes of Health, Bethesda, MD, USA). Measurements
were normalized to the amount of immunoreactivity of
the same protein in the input samples. Unstimulated
conditions were set at 100% for relative comparisons.
ELISA
Cells were serum-starved for 1 hour prior to stimulation
with 10 ng/ml TNF-α. SH-SY5Y cells were stimulated for
4 hours before being rinsed, then replaced with fresh
serum-free media to eliminate detection of TNF-α,
which was used to stimulate cells. Media were collected
20 hours later from SH-SY5Y cells or 24 hours after
stimulation of mouse primary cortical neurons. Media
were briefly centrifuged at low speed after being col-
lected. We followed the manufacturer’s instructions for
performing and analyzing the Human TNF-α ELISA Kit
(Invitrogen) and the mouse MCP-1 Quantikine ELISA
Kit (R&D Systems). Each sample was run in duplicate.
Nuclear fractionation
Fractionation was performed as described previously
[35]. Briefly, cells were rinsed in PBS, then harvested in
cold extraction buffer (10 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid, pH 7.6, 60 mM KCl,
1 mM ethylenediaminetetraacetic acid (EDTA), 0.1%
NP-40, 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl
fluoride (PMSF), Halt Phosphatase Inhibitor Cocktail and
PIC). Cells were spun at 200 g for 5 minutes. The super-
natant was collected as the cytoplasmic fraction. The pellet
was rinsed in cold extraction buffer without NP-40. The
pellet was resuspended in nuclear extraction buffer
(20 mM Tris, pH 8.0, 420 mM NaCl, 1.5 mM MgCl2,
0.2 mM EDTA, 0.5 mM PMSF, 25% glycerol, Halt Phos-
phatase Inhibitor Cocktail and PIC). The final salt concen-
tration was adjusted to 400 mM before lysates were kept
on ice for 10 minutes with occasional agitation. Lysates
were spun at 16,000 g for 10 minutes, and the supernatant
was collected as the nuclear fraction. Fractions were exam-
ined using immunoblot analysis. Densitometric measure-
ments for actin, histone 1 and p65 immunoreactivity in
cytoplasmic and nuclear fractions were performed using
ImageJ software. p65 measurements were normalized to
the amount of immunoreactivity of the loading control.
Unstimulated conditions were set at 100% to make relative
comparisons.
Statistical analysis
Statistical analysis was performed using GraphPad Prism
version 4.03 software (GraphPad Software, Inc, La Jolla,
CA, USA). One-way analysis of variance (ANOVA) was
performed for analysis of qRT-PCR for RNF11 levels and
luciferase assays. Tukey’s posttest was used for the luci-
ferase assay with mutant RNF11 constructs, and Bonfer-
roni posttests were used for the remaining ANOVAs.
Two-way ANOVAs with repeated measures were
performed for analysis of p65 translocation, and standard
two-way ANOVA was used to analyze the mRNA and
protein expression of inflammatory markers and the densi-
tometric analysis of p65 fractions. Bonferroni posttests
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were performed for all two-way ANOVAs. Densitometric
analysis of co-IPs was performed using paired t-tests. Statis-
tical significance was set at P< 0.05. All experimental
results are presented as means±SEM for at least three in-
dependent experiments.
Results
RNF11 modulates TNF-α-induced neuronal NF-κB
activation
To examine the effects of RNF11 on neuronal NF-κB sig-
naling, we transduced SH-SY5Y cells with lentivirus expres-
sing shRNA targeted against RNF11 (shRNA-RNF11 cells)
or scramble shRNA sequence (shRNA-Scramble cells).
qRT-PCR was used to measure the efficiency of RNF11
knockdown. The endogenous RNF11 mRNA level was
reduced by 75% in shRNA-RNF11 cells compared to
untransduced cells (P< 0.05) and shRNA-Scramble cells
(P< 0.05) (Figure 2A). To measure the activity of NF-κB
signaling in these cell lines, shRNA-RNF11 cells and
shRNA-Scramble cells were transiently cotransfected with
plasmids containing an NF-κB response element driving
expression of firefly luciferase or the T7 promoter driving
expression of Renilla luciferase. TNF-α specifically binds
and cross-links TNFR-1 and TNFR-2, which are members
of the TNFR superfamily and are constitutively expressed
in the brain; moreover, binding of TNF-α to its receptors
causes downstream activation of NF-κB signaling in neu-
rons [36]. Cells were exposed to 0 or 10 ng/ml of TNF-α
for 6 hours. NF-κB-dependent firefly luciferase activity
levels were normalized to control Renilla luciferase activity,
and the level of NF-κB activity was calculated as the fold
change between stimulated and unstimulated samples.
Stimulation with TNF-α caused a 10-fold increase in NF-
κB activity in the shRNA-RNF11 cells, which was signifi-
cantly different from the observed 3-fold increase in NF-κB
activity in untransduced cells (P< 0.001) and shRNA-
Scramble cells (P< 0.001) (Figure 2B). No difference was
observed between shRNA-Scramble cells and untransduced
cells. These results indicate that reduced expression of
RNF11 increases NF-κB activation in neuroblastoma cells.
Canonical NF-κB signaling involves phosphorylation of
IκBα by the IκB kinase (IKK) complex as a result of up-
stream receptor and associated complex activation. IκBα
is a cytoplasmic protein that binds NF-κB transcription
factors, including p65, to inhibit their activity. Phosphor-
ylation of IκBα releases p65 and other transcription fac-
tors from the complex and allows them to translocate to
the nucleus and drive NF-κB-dependent transcription
[37]. To investigate whether changes in RNF11 expres-
sion affect p65 translocation to the nucleus, we immu-
nostained shRNA-RNF11 and shRNA-Scramble cells
with p65 and Hoechst 333258, a nuclear stain, and
analyzed them for p65 colocalization with Hoechst
333258 following stimulation with TNF-α for 0, 30, 60
or 120 minutes. The fold change in colocalization at
steady state for each cell line was calculated. After 30
minutes of stimulation, an increase in p65 immunor-
eactivity in the nucleus was observed in all cell lines.
Representative images are shown in Figure 3A, and
quantification is shown in Figure 3B. p65 overlap with
Figure 2 Increased NF-κB luciferase activity in neuronal cells with knockdown of RNF11. (A) Stable SH-SY5Y cell lines were generated using
lentiviruses containing a control scramble small hairpin RNA (shRNA) sequence (shRNA-Scramble cells) or shRNA targeted against RNF11
(shRNA-RNF11 cells). Quantitative RT-PCR was used to measure relative RNF11 mRNA levels with glucuronidase β as an internal control. Values are
expressed as mean comparative cycle threshold± SEM of triplicate experiments. (B) Stable SH-SY5Y cell lines, as well as untransduced cells, were
transiently cotransfected with luciferase and Renilla plasmids and stimulated with 10 ng/ml TNF-α or PBS for 6 hours. Values represent the fold
change in NF-κB-dependent activity as measured by the ratio of luciferase to Renilla luminescence in stimulated over unstimulated samples ± SEM
in triplicate experiments. *P< 0.05; ***P< 0.001.
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Hoechst 333258 decreased at 60 minutes, as well as at
120 minutes, to the levels observed at 0 minutes. The
overlap between p65 and Hoechst 333258 in both
untransduced and shRNA-Scramble cells was similar to
levels observed at 0 minutes. Conversely, the amount of
p65 overlap with Hoechst 333258 at 120 minutes was
nearly 60% higher in shRNA-RNF11 cells than in
untransduced cells (P< 0.01) or shRNA-Scramble cells (P
< 0.01). No significant differences between untransduced
and shRNA-Scramble cells were observed at any time
point.
To validate RNF11’s effects on NF-κB signaling in pri-
mary cells, analyses for p65 translocation were per-
formed in murine cortical neurons. Neurons were
transduced with lentivirus driving expression of shRNA
targeted against RNF11 or a scramble shRNA sequence,
and qRT-PCR analyses revealed approximately 85%
knockdown of endogenous RNF11 in shRNA-RNF11
Figure 3 Prolonged nuclear p65 translocation after TNF-α stimulation observed in neuronal cells with knockdown of RNF11.
(A) SH-SY5Y cell lines (untransduced, small hairpin RNA (shRNA)-RNF11, shRNA-Scramble) were stimulated with TNF-α for 0, 30, 60 or 120 minutes.
Cells were immunostained for p65 (red) and nuclear DNA (Hoechst 333258, blue). Representative images obtained at 0, 30 and 120 minutes after
stimulation are shown. (B) Cells were analyzed for overlap of p65-positive and Hoechst 333258-positive pixels. The fold change in percentage
overlap of p65- and Hoechst 333258-positive pixels was calculated relative to unstimulated conditions. (C) Murine primary cortical neurons were
treated with cytosine arabinoside and transduced with lentiviruses containing shRNA targeted against RNF11 (shRNA-RNF11 neurons) or scramble
shRNA sequence (shRNA-Scramble neurons). Quantitative RT-PCR (qRT-PCR) was used to measure relative RNF11 mRNA levels. (D) shRNA-RNF11
or shRNA-Scramble neurons were stimulated for 0, 30 or 120 min before being immunostained for p65 and Hoechst 333258. Transduced cells
were analyzed for overlap of p65- and Hoechst 333258-positive cells. The fold change in percentage overlap of p65- and Hoechst 333258-positive
pixels was calculated relative to unstimulated conditions. (E) shRNA-Scramble and shRNA-RNF11 cells were stimulated for 0, 30 or 120 minutes.
Cytoplasmic and nuclear fractions were resolved by SDS-PAGE. (F) ImageJ software was used to quantify the ratio of the densitometry of the p65
bands in the nuclear fractions to the density of histone 1 immunoreactivity. The ratio for each time point was compared relative to the
steady-state ratio, which was set at 100%. (G) ImageJ software was used to quantify the ratio of the densitometry of the p65 bands in the
cytoplasmic fractions in a manner similar to that described in (F). All p65 colocalization values are means ± SEM of triplicate experiments. qRT-PCR
values are expressed as mean comparative cycle threshold ± SEM of triplicate experiments. Western blots of cytoplasmic and nuclear fractions
were run from triplicate experiments. **P< 0.01; ***P< 0.001.
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neurons compared to untransduced neurons (P< 0.001)
and shRNA-Scramble neurons (P< 0.001) (Figure 3C).
No significant difference in RNF11 expression was
observed between untransduced and shRNA-Scramble
neurons. Neurons were analyzed for colocalization of
p65 and Hoechst 333258 following stimulation with
TNF-α for 0, 30 and 120 minutes. After 30 minutes of
TNF-α stimulation, an approximately twofold increase
in p65 immunoreactivity in the nucleus was observed
under both conditions (Figure 3D). At 120 minutes post-
stimulation, p65 overlap with Hoechst 333258 in
shRNA-Scramble cells was similar to levels observed at
0 minutes, whereas colocalization between p65 and
Hoechst 333258 remained elevated in shRNA-RNF11
cells (P< 0.01) (Figure 3D). The results of these experi-
ments reveal that reduced RNF11 expression leads to
persistent p65 localization to the nucleus. Coupled with
the NF-κB reporter analyses described above, these
results strongly suggest that RNF11 is a negative regula-
tor of neuronal NF-κB signaling.
To support the p65 immunofluorescence data,
SDS-PAGE was performed to examine p65 levels in
cytoplasmic and nuclear fractions from SH-SY5Y
shRNA-Scramble and shRNA-RNF11 cells that were
isolated after 0, 30 or 120 minutes of TNF-α stimulation.
Western blot analyses revealed that p65 immunoreac-
tivity decreased in the cytoplasmic fraction by 78% but
increased more than sevenfold in the nuclear fraction
after 30 minutes of TNF-α stimulation in shRNA-
Scramble cells (see Figure 3E and quantification in
Figures 3F and 2G). After 120 minutes of TNF-α exposure,
p65 immunoreactivity decreased in the nuclear fraction
and increased in the cytoplasmic fraction to approxi-
mately steady-state levels in the shRNA-Scramble sam-
ples. In contrast, levels of p65 immunoreactivity from
shRNA-RNF11 samples after 30 and 120 minutes of
stimulation in the cytoplasmic and nuclear fractions
did not significantly change. We observed an approxi-
mately 70% decrease from steady state at both time
points in the cytoplasmic fractions and more than 6.5-
fold and 5-fold increases at 30 and 120 minutes, respect-
ively, from steady state in the nuclear fractions (P< 0.001).
These results are consistent with our hypothesis that
RNF11 is a negative regulator of TNF-α-induced canonical
NF-κB signaling in neurons.
Neuronal RNF11 dynamically associates with the A20-
ubiquitin editing protein complex
The results of previous studies in a monocyte cell line
suggest that united members of the A20 ubiquitin-editing
protein complex are required for mitigation of the canonical
NF-κB signaling pathway [38]. The essential members of
the complex are the deubiquitinase and E3 ligase A20, the
E3 ligase Itch, TAX1BP1 and RNF11 [16,19]. The A20
ubiquitin-editing protein complex is responsible for deubi-
quination of K63 ubiquitin linkage on receptor interacting
protein 1 (RIP1) and attachment of K48 ubiquitin linkage to
RIP1, which thereby facilitates proteasomal degradation of
RIP1 and termination of NF-κB signaling [37]. To deter-
mine whether RNF11 associates with the A20 ubiquitin-
editing protein complex in a neuronal system, we per-
formed coimmunoprecipitation (co-IP) experiments in N2A
cells. Because of low endogenous expression of RNF11,
N2A cells were transduced with lentivirus expressing wild-
type RNF11 tagged with a V5 epitope (N2A V5-RNF11).
Additionally, owing to the low level of endogenous A20,
N2A V5-RNF11 cells were transiently transfected with plas-
mid expressing FLAG-tagged A20 (FLAG-A20). V5-RNF11
immunoprecipitates were enriched with A20 immunoreac-
tivity, and control immunoprecipitates with V5 antibody
omitted were absent of A20 (Figure 4A). Reciprocal co-IPs
revealed that RNF11 was enriched in FLAG pull-down
assays for FLAG-A20 (Figure 4B), indicating that RNF11
and A20 associate in neuroblastoma cells. In parallel, co-IPs
were performed to examine RNF11’s association with Itch.
Pull-down assays with V5 antibody from N2A V5-RNF11
cell lysates were enriched with Itch immunoreactivity,
whereas control co-IPs with V5 antibody omitted were ab-
sent for Itch (Figure 4C). Reciprocal co-IPs showed V5-
RNF11 enrichment in endogenous Itch immunoprecipitates
(Figure 4D). These findings indicate that RNF11 associates
with A20 and Itch in neuronal cell lines and suggests that at
least a portion of the A20 ubiquitin-editing protein complex
exists in neuronal systems.
To determine whether TNF-α stimulation affects
RNF11’s association with the A20 ubiquitin-editing pro-
tein complex, co-IP experiments were performed in pri-
mary neurons following stimulation with TNF-α for 0 or
30 minutes. RNF11 immunoprecipitates were enriched
with A20 immunoreactivity at steady state and following
TNF-α stimulation (Figure 4E), and a significant increase
in A20 immunoreactivity was observed following TNF-α
stimulation for 30 minutes in RNF11 immunoprecipi-
tates (0 minutes: 100%, 30 minutes: 128.7%; P< 0.05)
(Figure 4F). Additionally, parallel co-IP experiments were
conducted to examine the association between RNF11
and Itch following TNF-α stimulation. RNF11 immuno-
precipitates were enriched with Itch immunoreactivity
under both steady-state and TNF-α stimulation condi-
tions (Figure 4H), and, like A20, a significant increase in
Itch immunoreactivity was observed in RNF11 immuno-
precipitates following stimulation with TNF-α (0 minutes:
100%, 30 minutes: 165.8%; P< 0.05) (Figure 4I). Import-
antly, RNF11 levels were similar for all immunoprecipi-
tates (see Figures 4E and 3H, with quantification shown in
Figures 4G and 3J). These results demonstrate that RNF11
can exist in complexes with A20 and Itch in neurons and
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that TNF-α stimulation enhances the association of A20
and Itch with RNF11.
The myristoylation domain is necessary for RNF11-mediated
inhibition of NF-κB signaling
The myristoylation domain of RNF11 is necessary for
proper recruitment to early endosomes, whereas the
PPxY motif is important for RNF11’s associations with
Itch-, Smurf2- and Nedd4-like proteins [23,39]. The
RING domain of RNF11 is important for interactions
with proteins involving ubiquitination and degradation
[22]. Although the substrate for RNF11’s putative E3 ubi-
quitin ligase activity has yet to be reported, researchers
in previous studies have identified mutations that inter-
fere with the ubiquitination activity of the RING domain
in analogous E3 ubiquitin ligases [40]. Mutations of
cysteines or histidines within the RING domain cause
structural changes that prevent E2 binding and ubiquiti-
nation, whereas an isoleucine mutation within the RING
domain prevents interactions with E2 enzymes but keeps
Figure 4 Dynamic associations of RNF11 with both A20 and Itch in primary neurons. N2A cells transduced with V5-RNF11 lentivirus (N2A
V5-RNF11) and transfected with FLAG-A20 were harvested for immunoprecipitation (IP) with V5 antibody (A) or harvested for IP with FLAG
antibody (B). Proteins were resolved by SDS-PAGE and immunoblotted with anti-A20 and RNF11. In parallel, pull-down assays with V5 antibody
(C) or with Itch antibody (D) from N2A V5-RNF11 cell lysates were resolved by SDS-PAGE. Immunoprecipitates and lysates were immunoblotted
with anti-Itch and RNF11. (E) and (H) Murine primary cortical neurons were stimulated with 10 ng/ml TNF-α for 0 or 30 minutes and harvested for
IP with RNF11 antibody. Control IP experiments were performed with antibody omitted. Proteins were resolved by SDS-PAGE and immunoblotted
with anti-A20, Itch, RNF11 and actin. (F), (G), (I) and (J) ImageJ software was used to quantify the densitometry of the immunoprecipitated bands
relative to the 0-minutes time point. Each input sample’s immunoreactivity was used as a loading control. All IPs are representative of at least
three independent experiments. *P< 0.05.
Pranski et al. Journal of Neuroinflammation 2012, 9:67 Page 9 of 16
http://www.jneuroinflammation.com/content/9/1/67
the RING domain structure intact [41]. We generated
RNF11 mutants for each of these domains to examine
their importance with respect to RNF11’s influence over
neuronal NF-κB signaling (Figure 5A). A myristoylation
mutant was made by substituting alanine for glycine 2
(RNF11-G2A) [39], and a PPxY motif mutant was con-
structed by substituting alanine for tyrosine 40 to abolish
binding with Nedd4-like proteins (RNF11-Y40A) [23,39].
RING domain mutants were generated by substituting
alanine for isoleucine 101 to prevent E2 binding
(RNF11-I101A) [41], or by substituting alanine for histi-
dine 119 and histidine 122 to abrogate RING domain
structure (RNF11-H2) [40], or by substituting alanine for
cysteine 99 to abolish proper RING domain folding
(RNF11-C99A) [40]. Importantly, additional site-directed
mutagenesis was performed to generate shRNA-resistant
forms of these RNF11 mutants. This approach allowed for
the expression of RNF11 mutants under reduced expres-
sion of endogenous RNF11 in NF-κB-dependent luciferase
assays and co-IPs (Figure 5B). Silent mutations were intro-
duced at glutamine 72 and arginine 73 [19] in wild-type
RNF11, the myristoylation mutant, the PPxY motif mutant
and the three RING domain mutants to generate the fol-
lowing shRNA-resistant RNF11 constructs: V5-WTR, V5-
G2AR, V5-Y40AR, V5-I101AR, V5-H2R and V5-C99AR,
respectively (Figure 5A).
To determine the impact of RNF11’s functional amino
acid motifs with respect to NF-κB signaling, we conducted
the luciferase assays described in Figure 2B. SH-SY5Y
shRNA-RNF11 cells were transiently cotransfected with
Figure 5 Myristoylation mutant of RNF11 is unable to alter NF-κB signaling. (A) Site-directed mutagenesis of V5-tagged wild-type RNF11
was used to create the myristoylation mutant (G2A), the PPxY motif mutant (Y40A) and RING domain mutants (C99A, H2, I101A). Small hairpin
(shRNA)-resistant mutants were created using Q72/R73 mutagenesis. The domains were as follows: M, myristoylation domain; PPxY, PPxY motif;
UIM, ubiquitin-interacting motif; and RING, RING-H2 domain. (B) Model of resistance experiments in SH-SY5Y cells. Stably transduced shRNA-RNF11
cells were transfected with shRNA-resistant RNF11 plasmids to determine which mutants behaved similarly to the endogenous protein in
luciferase and coimmunoprecipitation experiments. (C) SH-SY5Y shRNA-RNF11 cells were transfected with shRNA-resistant RNF11 mutants and
luciferase and Renilla constructs. Cells were exposed to 10 ng/ml TNF-α for 6 hours and subjected to a luciferase assay. Values represent the fold
changes in the ratios ± SEM of luciferase to Renilla luminescence of stimulated over unstimulated samples of triplicate samples in three
experiments. (D) Samples from (C) were resolved by SDS-PAGE and immunoblotted with RNF11 antibody. Blots are representative of three
independent experiments. *P< 0.05; ***P< 0.001.
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empty vector, V5-WTR, V5-G2AR, V5-Y40AR, V5-I101AR,
V5-H2R or V5-C99AR constructs, as well as plasmids con-
taining an NF-κB response element driving expression of
firefly luciferase or the T7 promoter driving expression of
Renilla luciferase. Cells were exposed to 0 or 10 ng/ml of
TNF-α, and luciferase readouts were measured after 6 hours
of TNF-α stimulation. Expression of V5-WTR, V5-H2R or
V5-I101AR in shRNA-RNF11 cells decreased NF-κB activity
by approximately 75% compared to vector-transfected cells
(P< 0.001) (Figure 5C). Transfection of V5-G2AR or V5-
C99AR did not significantly alter NF-κB activity in compari-
son to vector transfected cells, but was significantly different
from cells transfected with V5-WTR (P< 0.001). Last, ex-
pression of V5-Y40AR reduced NF-κB activity only 24%, a
significant difference from both vector and V5-WTR
(P< 0.05 for vector and V5-Y40AR; P< 0.001 for V5-WTR
and V5-Y40AR). Western blot analyses indicated similar ex-
pression levels of RNF11 mutants (Figure 5D). These results
suggest that the myristoylation domain is required and the
PPxY motif is necessary for the full effect of RNF11’s
influence over NF-κB activation as measured by lucifer-
ase assay. Moreover, cysteine 99 is required, but isoleu-
cine 101 or histidines 199 and 122 are dispensable, for
RNF11-mediated suppression of NF-κB activity under
these experimental conditions.
To determine whether mutations in the myristoylation
domain, PPxY motif or RING domain alter RNF11’s
association with the A20 ubiquitin-editing protein com-
plex, SH-SY5Y shRNA-RNF11 cells were transfected
with vector, V5-WTR, V5-G2AR, V5-Y40AR, V5-I101AR,
V5-H2R or V5-C99AR, and co-IPs for endogenous Itch
were performed. V5-WTR, V5-I101AR, V5-H2R and V5-
C99AR immunoprecipitates were enriched with Itch
immunoreactivity compared to vector control (Figures 6A
and 5B), whereas V5-G2AR immunoprecipitates were ab-
sent for Itch (Figure 6A). V5-Y40AR immunoprecipitates
displayed endogenous Itch immunoreactivity, although it
was reduced compared to V5-WTR immunoprecipitates
(Figure 6A). Additionally, SH-SY5Y shRNA-RNF11 cells
were transfected with vector, V5-WTR, V5-G2AR, V5-
Figure 6 Myristoylation mutant of RNF11 is unable to associate with Itch. SH-SY5Y shRNA-RNF11 cells were transfected with shRNA-resistant
RNF11 constructs or vector. Coimmunoprecipitation experiments using V5 antibody were performed 24 hours after transfection.
Immunoprecipitates and lysates were resolved by SDS-PAGE and immunoblotted with anti-A20, Itch, RNF11 or actin. Blots are representative of
three independent experiments.
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Y40AR, V5-I101AR, V5-H2R or V5-C99AR, as well as
FLAG-A20, and co-IPs for A20 were performed. The
immunoprecipitate of each RNF11 construct tested was
enriched with A20 immunoreactivity compared to vector
control (Figure 6C and 6D). These studies revealed that
the myristoylation domain is necessary for RNF11 associ-
ation with Itch and that the PPxY motif is also important.
On the basis of these results and the luciferase assays
described above, we hypothesize that disrupted RNF11-
Itch complex formation contributes to the impaired regu-
lation of NF-κB activation exhibited by the RNF11 myris-
toylation domain and PPxY motif mutants.
RNF11 influences inflammatory responses in neurons
Inflammation is tightly associated with NF-κB signaling
as well as with neurological disease; therefore, we investi-
gated whether RNF11 is linked to inflammatory response
induction. To test this hypothesis, SH-SY5Y shRNA-
RNF11 and shRNA-Scramble cells were exposed to 0 or
10 ng/ml TNF-α for 4 hours, and RNA was extracted to
examine by qRT-PCR the induction of inflammatory cas-
cades. Specifically, mRNA levels of the proinflammatory
cytokine TNF-α and the cytokine-inducible protein A20
were measured [42-45]. TNF-α is transcriptionally regu-
lated by NF-κB as well as by other inflammation-related
transcription factors; therefore, increased TNF-α mRNA
levels are generally indicative of an immune response in-
volving multiple signaling pathways [46]. Changes in A20
mRNA levels are linked more specifically to activity of NF-
κB signaling [47,48]. TNF-α stimulation increased A20
mRNA levels in shRNA-Scramble cells; however, a more
substantial increase in A20 mRNA levels was observed in
shRNA-RNF11 cells (shRNA-Scramble: 3.81-fold change,
shRNA-RNF11: 38.70-fold change; P< 0.001) (Figure 1A).
Similarly, TNF-α stimulation increased TNF-α mRNA
levels in shRNA-Scramble cells, but to a greater degree in
shRNA-RNF11 cells (shRNA-Scramble: 3.08-fold change,
shRNA-RNF11: 9.70-fold change; P< 0.001) (Figure 1B).
Importantly, steady-state levels of A20 and TNF-α mRNA
were not significantly different between shRNA-RNF11
cells and shRNA-Scramble cells. To further support these
findings, we performed a TNF-α ELISA to measure
secreted TNF-α protein levels. After serum starvation for
1 hour, cells were stimulated with 0 or 10 ng/ml TNF-α
for 4 hours. To minimize detection of the human recom-
binant TNF-α used to stimulate the cells, cells were rinsed
with serum-free media and incubated with a reduced vol-
ume of serum-free media for 20 hours. Basal levels of
TNF-α were similar in shRNA-Scramble (10.49 pg/ml)
and shRNA-RNF11 cells (below the limits of detection)
(Figure 1C). Recombinant TNF-α stimulation of the NF-
κB pathway increased production of TNF-α protein in
shRNA-Scramble cells and, to a larger extent, in shRNA-
RNF11 cells (shRNA-Scramble: 744.51, shRNA-RNF11:
1,285.03 pg/ml; P< 0.001).
To expand these studies to primary cells, murine cor-
tical neurons were transduced with lentivirus expressing
shRNA-Scramble or shRNA-RNF11 and MCP-1 mRNA
levels were measured. MCP-1 is a potent chemokine that
attracts monocytes, macrophages and microglia to sites
of injury to evoke further release of inflammatory mole-
cules, and it is involved in inflammatory neuropathologies
[47,49-51]. Importantly, like TNF-α and A20, MCP-1 is
transcriptionally regulated by NF-κB [52,53]. In our pri-
mary neuron-enriched cultures, we specifically examined
effects of reduction of the high RNF11 mRNA expression
in neurons (in comparison to glial cells, as shown in
Figure 1D) due to the cytosine arabinoside treatment
of our cultures. Stimulation with 10 ng/ml TNF-α
revealed a time-dependent increase in MCP-1 mRNA
levels at 4 and 24 hours poststimulation in shRNA-
Scramble neurons, whereas a greater increase was
observed at each time point in neurons transduced
with shRNA-RNF11 (shRNA-Scramble 0 hours: 1.02-
fold change, 4 hours: 6.38-fold change, 24 hours:
14.91-fold change; shRNA-RNF11: 0 hours: 1.81-fold
change, 4 hours: 25.73-fold change, 24 hours: 29.04-fold
change; P< 0.05 for both time and transduction differ-
ences) (Figure 1E). This result was confirmed by analyzing
MCP-1 protein levels from conditioned media of stimu-
lated cells. Transduced shRNA-Scramble or shRNA-
RNF11 primary cortical neurons were stimulated with 0 or
10 ng/ml TNF-α in a reduced volume of serum-free media
for 24 hours. Basal levels of MCP-1 were similar in media
collected from shRNA-Scramble (9.41 pg/ml) and shRNA-
RNF11 cells (9.53 pg/ml). TNF-α stimulation increased
MCP-1 protein levels in media collected from shRNA-
Scramble cells and, to a greater degree, from shRNA-
RNF11 cells (shRNA-Scramble: 1,976.60, shRNA-RNF11:
3,654.02 pg/ml; P< 0.001) (Figure 1F). These results
suggest that changes in RNF11 expression influence
mRNA and protein levels of gene products that are down-
stream targets of NF-κB signaling. Therefore, we propose
that RNF11 likely contributes to the mitigation of inflam-
matory responses exerted by neurons.
Discussion
NF-κB activity is essential for peripheral immune cell sur-
vival, and proper regulation of NF-κB signaling is critical
for mounting a normal immune response [54]. Persistent
activation of the NF-κB pathway is known to promote in-
flammation and inflammatory diseases [54,55], including
progressive neurodegenerative diseases [2-11]. Notably, in-
hibition of NF-κB activity has been demonstrated to attenu-
ate neuroinflammation and cell death in animal models of
PD, Alzheimer disease (AD) and ischemia [5,8,9,56,57]. In
this study, we investigated the role of neuronal RNF11 as a
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component of the A20 ubiquitin-editing complex in regu-
lating TNF-α-induced canonical NF-κB activity by targeted
knockdown of endogenous RNF11 in human neuroblast-
oma cells and primary neuronal cultures. Our analyses
revealed that (1) neuronal RNF11 acts as a negative regula-
tor of the canonical NF-κB signaling pathway, (2) neuronal
RNF11 associates with the A20 ubiquitin-editing protein
complex, (3) the myristoylation and PPxY domains of
RNF11 are required and necessary, respectively, for RNF11’s
effects on NF-κB signaling and association with Itch, a
member of the A20-ubiquitin editing protein complex
and (4) reduced expression of RNF11 in neurons can
result in aberrant regulation of inflammatory signaling.
Together these findings suggest that RNF11 has a critical
role in the regulation of canonical NF-κB signaling in the
central nervous system.
NF-κB responds to a diverse series of inflammatory
activators, including ultraviolet light, double-stranded
RNA, cytokines, vasoactive peptides and viral oncogenes
[58]. Stimulation of the NF-κB signaling pathway causes
transcription of various inflammatory markers, including
inducible chemokines, cell adhesion molecules and vaso-
active and antiapoptotic proteins important in the cellu-
lar stress response to effective control of inflammation
[59]. The signaling pathway also has several levels of
autoregulation, one of which includes the activation and
association of the RIP1 and IκB kinases by the A20
ubiquitin-editing protein complex [59]. Through the deg-
radation of RIP1 and the disruption of the association
between RIP1 and IKK, the A20 ubiquitin-editing pro-
tein complex efficiently halts canonical NF-κB signaling
[59]. Outside the nervous system this complex requires
the association of A20, Itch, TAX1BP1 and RNF11 to en-
hance K48 ubiquitination of RIP1 and promote RIP1 tar-
geting to the proteasome [16,19]. Recently, a human
genomewide siRNA screen identified RNF11 as an im-
portant modulator of canonical NF-κB activity in HEK-
293 cells [60]. In this report, we have demonstrated that
reduction of RNF11 in primary cortical neurons sus-
tained canonical NF-κB signaling, most likely by RNF11’s
lack of association with the A20 ubiquitin-editing protein
complex. A yeast two-hybrid screen revealed that Itch,
TAX1BP1, NF-κB essential modulator and A20 are po-
tential binding partners of RNF11 [25]. Other research-
ers have reported associations of RNF11 with glutathione
S-transferase -tagged Itch in breast cancer cell lines [21],
tagged RNF11 with tagged TAX1BP1 and A20 in HEK
cells [19] and RNF11 with A20, TAX1BP1 and RIP1 in
mouse embryonic fibroblasts and blood-derived macro-
phages [19]. Our present work reveals that RNF11
associates with Itch and A20 in neuronal systems and
that there is an increased association of A20 and Itch
with RNF11 after TNF-α stimulation (Figure 4). This
phenomenon may be due to enhanced stability of the
A20 ubiquitin-editing protein complex through protein
changes such as posttranslational modifications. Import-
antly, our data suggest that neurons, similarly to mono-
cytic cells [19], form an A20 ubiquitin-editing protein
complex to garnish transient reactions for regulating the
canonical NF-κB signaling pathway.
Our studies involving RNF11 mutants indicate that the
myristoylation domain is imperative for RNF11’s effects
on NF-κB activity as well as for association with the A20
ubiquitin-editing protein complex (Figures 5 and 6). Mu-
tagenesis of glycine 2 disrupts the protein’s ability to in-
corporate myristoylic acid, causing a shift in localization
from cytosolic vesicle-like structures to a more diffuse
pattern throughout the cell [39]. Furthermore, mutation
of RNF11’s glycine 2 prevents association and ubiquitina-
tion by Itch and Nedd4 [39]. V5-G2AR most likely does
not localize to intracellular compartments, where it inter-
acts with other members of the A20 ubiquitin-editing pro-
tein complex and therefore fails to reduce NF-κB-induced
luciferase activity and co-IP with Itch (Figures 5C, 6A and
6 C).
RNF11 also harbors a PPxY motif that previously has
been shown to be important for associations with Itch
and other Nedd4-like proteins [19,21,39,61]. In contrast,
we have shown in this study that V5-Y40AR associated
with endogenous Itch in neuroblastoma cells, although
Itch immunoreactivity was reduced compared to wild-
type RNF11. Santonico et al. proposed that RNF11 may
have an alternative binding site (VPxY) for Itch and
structurally similar proteins [39], which may explain why
we observed some degree of Itch and RNF11 interaction.
Santonico et al. believe that this nearby site explains why
some degree of RNF11 ubiquitination by Itch occurs
when the consensus PPxY site is mutated. It would be
interesting to explore whether this site is important for
interactions with Itch or how a double-PPxY and VPxY
mutation would affect RNF11 association with the A20
complex. Additionally, we observed some reconstitution
of negative regulation of NF-κB signaling following ex-
pression of V5-Y40AR, whereas Shembade et al. did not
[19]. This contrast may be attributed to experimental dif-
ferences in measuring NF-κB signaling. Shembade et al.
used Western blot analysis to examine transient phos-
phorylation of IκBα and JNK, whereas we employed
quantitative luciferase assays.
The three RNF11 constructs we generated harboring
RING domain mutations all maintained interactions
with Itch and A20 (Figure 6B and 6D). Previously,
Shembade et al. showed that RNF11 with a mutation of
cysteine 99 to alanine was unable to associate with
A20, TAX1BP1 or RIP1 in TNF-α-stimulated THP-1
cells [19]. Similarly to our studies, Santonico et al.
found that an RNF11 RING domain mutant with ser-
ines substituted at cysteines 99 and 102 retained
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binding to Itch in HEK cells [39]. This discrepancy may
underlie a putative difference between innate immune cells
and other human cell lines in the stability and transient
nature of the associations among A20-ubiquitin protein
complex members.
The RING domain mutants we examined altered NF-κB-
dependent luciferase activity differently, despite maintaining
associations with Itch and A20. Although the mutation of
isoleucine 101 and the mutations of histidines 119 and 122
recapitulated effects of wild-type RNF11, the mutation of
cysteine 99 did not mimic wild-type RNF11 in this assay.
Similarly, Shembade et al. showed that mutation of cysteine
99 to alanine was unable to restore negative regulation of
NF-κB signaling in siRNA rescue experiments [19]. The
results of our study support these data and add quantitative
assessment of luciferase-dependent NF-κB activity of this
mutant (Figure 5C). However, the incongruity between the
three RING domain mutants in the NF-κB-dependent luci-
ferase assay highlights an essential remaining question: Is
RNF11’s E3 ubiquitin ligase activity critical for negative
regulation of NF-κB signaling by the A20 complex?
NF-κB family proteins and the A20 ubiquitin-editing
protein complex, though differentially distributed in vari-
ous cells, are highly expressed in peripheral immune cells,
including lymphocytes and macrophages [38,54,62-64].
RNF11 mRNA and protein levels are higher in neurons
than in glial cells, including microglia (Figure 1D). The
reason for this differential expression in neurons is not
clear, but could be a protective strategy in postmitotic cells
which have a limited lifespan and limited tolerance to
chronic NF-κB activation and neuroinflammation [19].
Our studies show that reduced levels of RNF11 in neu-
rons increase production of the inflammatory cytokine
MCP-1 following TNF-α activation (Figure 1). Other
agents targeting NF-κB signaling (that is, Nurr1, α-synu-
clein, amyloid-β) have been shown to increase production
of inflammatory cytokines [10,65-68]. In neurodegenera-
tive disease and ischemic attack, it is hypothesized that
signals sent from damaged neurons and glial cells cause
activation of NF-κB signaling [69]. Chronic stimulation of
the NF-κB signaling cascade brings about increased pro-
duction of inflammatory molecules such as TNF-α, nitric
oxide and IL-1, resulting in oxidative stress and neuronal
degeneration [70-72]. This can be observed in the brains
of patients with stroke, AD, PD, ALS and other neurode-
generative diseases [7,73-77], and it has been hypothesized
that the pathogenesis and progression of neurological dis-
eases is in part due to dysregulation or chronic activation
of the NF-κB pathway [6,78,79]. Notably, RNF11 is a can-
didate gene for PD [80] and colocalizes with α-synuclein-
positive Lewy bodies and neurites in PD patients [20]. Our
future studies will focus on investigating the role of
RNF11 as a regulator of neuroinflammation in animal
models of neurodegenerative diseases.
Conclusions
Given the mounting evidence that neuroinflammation is
heightened in neurodegenerative diseases [5,8,9,56,81],
we conclude that functionally compromised or reduced
expression of RNF11 could result in persistent NF-κB
activation and could promote chronic neuroinflamma-
tion. Further studies will explore these hypotheses in
relevant animal models to ascertain how RNF11 expres-
sion levels affect NF-κB signaling in vivo. Additionally,
the impact of posttranslational modifications on RNF11
activity will be explored to gain further understanding of
RNF11’s role within the A20 ubiquitin-editing protein
complex in neurons.
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